Sort   by:  
 Page size 
MetabolomicsDynamic change of IDO1 activity predicts survival in patients with unresectable stage III NSCLC and chemoradiotherapy

OBJECTIVES: High activity of Indoleamine 2,3-dioxygenase1 (IDO1) in lung cancer patients converts tryptophan (Trp), which is the essential amino acid for T cell metabolism, to kynurenine (Kyn) and consequently suppresses anti-tumor immune responses. We aimed to track the dynamics...

2022-08-05 | MTBLS5267 | MetaboLights
MetabolomicsLC-MS/MS Quantification of Nuclear α-KG in NSCLC
This study contains targeted LC-MS/MS quantification of α-ketoglutarate (α-KG) in NSCLC cells using 13C-labeled α-KG internal standard. Nuclear α-KG levels were measured in A549, A549/DTX, PC9, and PC9/OR cells. In addition, nuclear α-KG was quantified in GLUD1-overexpressing A549 cells and GLUD1-kn...
2026-07-21 | MTBLS15115 | MetaboLights
MetabolomicsLactobacillus rhamnosus GG (LGG) exhibits inhibitory effects against non-small cell lung cancer (NSCLC) and alleviates the adverse effects associated with gefitinib_Serum metabolomics study in mice

After screening the bacteria both in vivo and in vitro, it was found that a certain candidate strain could significantly inhibit non-small cell lung cancer when combined with the drug gefitinib and alleviate the side effects of gefitinib. Next, the mechanism will be explored through in vivo and i...

2026-09-03 | MTBLS13812 | MetaboLights
MetabolomicsLactobacillus rhamnosus GG (LGG) exhibits inhibitory effects against non-small cell lung cancer (NSCLC) and alleviates the adverse effects associated with gefitinib_Fecal metabolomics study in mice

After screening the bacteria both in vivo and in vitro, it was found that a certain candidate strain could significantly inhibit non-small cell lung cancer when combined with the drug gefitinib and alleviate the side effects of gefitinib. Next, the mechanism will be explored through in vivo and i...

2026-09-03 | MTBLS13811 | MetaboLights
MetabolomicsLactobacillus rhamnosus GG (LGG) exhibits inhibitory effects against non-small cell lung cancer (NSCLC) and alleviates the adverse effects associated with gefitinib_Metabolite study of culture medium supernatant

After screening the bacteria both in vivo and in vitro, it was found that a certain candidate strain could significantly inhibit non-small cell lung cancer when combined with the drug gefitinib and alleviate the side effects of gefitinib. Next, the mechanis...

2026-09-03 | MTBLS13843 | MetaboLights
MetabolomicsSearching for Drug Synergy Against Cancer Through Polyamine Metabolism Impairment: Insight Into the Metabolic Effect of Indomethacin on Lung Cancer Cells
Non-small cell lung cancer (NSCLC) is the most lethal and prevalent type of lung cancer. In almost all types of cancer, the levels of polyamines (putrescine, spermidine, and spermine) are increased, playing a pivotal role in tumor proliferation. Indomethacin, a non-steroidal anti-inflammatory drug, ...
2021-02-08 | MTBLS873 | MetaboLights
MetabolomicsNon-invasive urinary metabolomic profiling identifies diagnostic and prognostic markers in lung cancer
Lung cancer remains the most common cause of cancer deaths worldwide, yet there is currently a lack of diagnostic noninvasive biomarkers that could guide treatment decisions. Small molecules (<1500 Da) were measured in urine collected from 469 lung cancer patients and 536 population controls using u...
2014-05-06 | MTBLS28 | MetaboLights
MetabolomicsBifidobacterium animalis subsp. lactis V9 Overcomes CYFRA 21-1-Linked Immunochemotherapy Resistance in NSCLC via Microbial Metabolites

Elevated serum cytokeratin 19 fragment (CYFRA 21-1) marks aggressive disease

and poor response to immunochemotherapy in advanced non-small cell lung cancer

(NSCLC), but its link to gut microbiome dysfunction remains unclear. We show that

high CYFRA 21-1 levels correlate with dep...

2026-07-21 | MTBLS13300 | MetaboLights
MetabolomicsBifidobacterium animalis subsp. lactis V9 Overcomes CYFRA 21-1-Linked Immunochemotherapy Resistance in NSCLC via Microbial Metabolites

Elevated serum cytokeratin 19 fragment (CYFRA 21-1) marks aggressive disease

and poor response to immunochemotherapy in advanced non-small cell lung cancer

(NSCLC), but its link to gut microbiome dysfunction remains unclear. We show that

high CYFRA 21-1 levels correlate with dep...

2026-07-21 | MTBLS13296 | MetaboLights
MetabolomicsCirculating cell populations as response predictors and targets to improve immunotherapy in metastatic lung cancer

The effectiveness of immunotherapy varies among patients with advanced non-small cell lung cancer (NSCLC). Here we investigated the baseline immune status in stage IV NSCLC patients treated with anti-PD-1 plus chemotherapy to understand the immune mechanisms and unveil systemic markers associated...

2025-10-16 | MTBLS13150 | MetaboLights
Sort   by:  
 Page size